Development of technologies that exploit adenoviruses as highly efficient vectors for gene therapy. Includes a range of publications with abstract links.

A network of researchers looking to foster collaboration in several therapeutic fields.

NucleofectorTM technology allows non-viral gene transfer directly into the nucleus of primary cells and cell lines, thereby providing rapid target gene validation, acceleration of drug development and new applications for gene therapy.

Organization dedicated to promoting gene therapy research through public education, scientific meetings and scientific committees targeting specific therapeutic areas and also vector technology.

Focused on developing gene therapies for lipoprotein lipase disorder, inflammatory bowel disease and neuroregeneration. Also provides contract development and manufacturing of gene and cell-based products in their GMP facility.

A gene medicine company developing a broad range of products based on vascular and endothelial molecular biology to treat vascular and circulatory diseases and cancer.

Gene delivery technology allowing pharmaceutical and genomics companies to assess the therapeutic value of identified genes and also allows genes to be used as therapeutic products to treat diseases from cancer to nervous and immune system disorders

Focused on the development and commercialization of cancer vaccines and gene therapies to treat various cancers including leukemia, hemophilia A and B, restenosis after angioplasty and Parkinson's disease.

Clinical and fundamental research, job opportunities, faculties' interests and links to gene therapy sites - joint project of Baylor College of Medicine, Texas Children's Hospital, and The Methodist Hospital in Houston, TX.

The center links basic science, clinical investigation and technology transfer endeavors in the area of gene therapy, while also serving as a resource for information and education.

The mission of the Centre is to investigate, create and implement approaches utilizing the delivery of genes as therapeutic agents in the treatment of human and animal disease.

Pioneering genetic therapies for neurologic disorders.

A product-driven cardiovascular gene therapy company, focused on the discovery, development and commercialization of novel and innovative non-surgical gene therapy products.

Developing human gene therapy products for cystic fibrosis and hemophilia B and DNA vaccinations. The company creates proprietary PLASmin Complexes which are efficient non-viral vectors and REPLIsome vectors which allow replication of non-viral vectors.

Discover, develop and produce a variety of biopharmaceuticals for the treatment of human diseases. Includes technology and investors data, and careeer opportunities.

Conducts basic biomedical research into therapies for Down Syndrome, ALS, cancer, and Rec8 Syndrome. Includes map of chromosone 21, employment details and links to related resources.

Develop technology to manufacture therapeutic proteins through genetic modification of gastrointestinal cells to find a cure for diabetes and its complications.

Organises annual meetings in Europe to promote gene therapy research.

Fosters the exchange of ideas between research groups and individual scientists, organizes scientific meetings and training courses and informs general public about basic aspects and recent developments in gene therapy.

Provide gene assays to assist pharmaceutical and biotech companies with new drug development and multi-gene expression analysis services to researchers. Includes technology and investor data, and careers.

Definition, hurdles, ethical issues, and links to more resources on gene therapy provided by the Oak Ridge National Laboratory.

Advises on the ethical acceptability of proposals for gene therapy research on humans taking account of the scientific merits and the potential benefits and risks, and provides advice to UK Health Ministers on developments in gene therapy research.

Development information for the clinical use of gene therapy for children with severe illnesses.

The human cancer gene prevention and therapy program conducts basic research, clinical trials and vector development.

Commercial firm providing reagents for gene delivery and gene therapy research, including unique pGeneGrip fluorescently labeled plasmid vectors and GenePORTER cationic lipid transfection reagent.

Commercial site focusing on the current state of retroviral vector development for gene therapy with numerous helpful links - from Nature Technology Corp.

A rapidly growing biopharmaceutical company that develops novel gene-based methods to treat human diseases.

An emerging biopharmaceutical company developing novel gene therapies for diseases where local delivery of a therapeutic gene has potential benefits over currently available treatments. New product development initiatives have been formalized for coronary artery disease with BioBypass angiogen, restenosis prevention and cancer.

Aims to enhance the development of safe and effective gene therapy by supporting research projects, from vector development and construction to production of biologicals for human use and their application in GCP clinical trials.

Provides plasmid construction and virus production services for gene therapy in both research and therapeutic applications.

A GMP biomanufacturing company located in Belgium, able to produce, purify and aseptically fill clinical batches of therapeutic proteins, monoclonal antibodies, plasmid DNA, vaccinal viruses or viral vectors for gene therapy.

Consortium of researchers from European institutions focused on developing gene therapy of hematopoietic stem cells for inherited diseases.

A leader in the development of gene therapy products to treat a variety of cancers.

Tools for gene therapy and cancer research including plasmid and cloning vectors, gene collections, selection antibiotics, mycoplasma curing kit, and prodrugs.

A registered charitable organization raising funds for research in gene and cell based therapies focusing on Duchenne muscular dystrophy and other neuromuscular diseases.

A development and manufacturing company based in San Diego dedicated to the production of high-quality, clinical grade, gene and cell based therapeutics and reagents.

The group performs basic research on viruses in order to facilitate the development of efficient gene-transfer vectors for use in gene therapy. Current research concerns the human adenoviruses and the systems required for producing recombinant-adenovirus vectors.

Sells AAV purification kits of different serotypes for gene therapy research. Includes online buying facilities.

An interactive group of academic production and pharmacology/toxicology laboratories whose primary goal is to provide eligible investigators with clinical grade vectors for phase I/II gene therapy clinical trials and to provide support for relevant pharmacology/toxicology studies leading up to clinical gene transfer protocols.

Monitors scientific progress and ethical issues in basic and clinical research involving recombinant DNA and human gene transfer at NIH funded institutions.

Perform genetic analysis on collections of family samples so as to understand the mechanisms and causes of common diseases, in order to identify new drug targets, the validation of targets and the development of diagnostics.

Focuses on developing gene transfer technologies for human gene therapy, gene-based immunotherapy, and gene-based drug discovery for cancer, AIDS, neurodegenerative and cardiovascular disease.

Focused on the development gene therapies for diseases of the airway, such as asthma, lung cancer and in particular, cystic fibrosis (CF). Work includes formulation development, reagent production, pre-clinical testing, and human clinical trials.

Fosters the growth and development of multidisciplinary preclinical and clinical research programs aimed at the use of gene transfer technologies for the treatment of human disease.

Dedicated to the development, manufacturing and marketing of modular transfection reagents. Expertise includes in vitro and in vivo gene, oligonucleotide and siRNA delivery, transient and stable cell transfection, automation and protein production in animal cells.

Develops separation and purification processes for manufacturing gene delivery products such as supercoiled plasmids, synthetic oligonucleotides, recombinant adenovirus and adeno-associated virus.

Focuses on the development of novel gene-based technologies and products providing first proof of principle data in pre-clinical models and then moving these technologies into the clinical setting.

Development of technologies controlling DNA replication for applications in a platform for gene therapy vectors and in the discovery of new therapeutic agents for cancer and tissue regeneration.

Virological research and clinical trials company that work on most model systems and carry out projects from laboratory based assays to full ethics committee approved clinical trials.

Aims to commercialize site-specific gene therapeutics and DNA devices for tissue repair and regeneration.

Develops gene delivery technologies and therapeutic products based on gene delivery.

A joint initiative of The New Children's Hospital and the Children's Medical Research Institute is undertaking gene therapy clinical trials in Australia. Research projects include cancer immunotherapy, vector development, HIV infection, targeting gene delivery to specific tissue types.

An information source on all aspects of human gene therapy. It offers an international comprehensive summary of both published and ongoing clinical trials. Also includes reviews on basic and therapeutic issues.

Gene therapy company based in France is developing products for cancer and cystic fibrosis. Vector platforms include adenovirus, retrovirus, vaccinia virus, cellular and synthetic vectors.

Facilitates the application of basic and pre-clinical research to the treatment of human disease through vector development and gene discovery and characterization.

Clinical gene therapy research programs focusing on metabolic disorders.

Working to translate gene therapy research from the laboratory bench into Phase I clinical trials for the treatment of hematologic and endocrine diseases. The center has a GMP facility for clinical grade gene vector production.

Developing gene-based therapeutics or "gene medicines" for the treatment of certain cancers, neuromuscular, cardiovascular, rheumatological and pulmonary diseases.

Sells virus purification kits for gene therapy and virus research which do not require cesium gradients.

A biotechnology company with a primary interest in cancer gene therapy.